In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
27 authors.
Nathan A OnaInstitute for RNA Innovation, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID 0000-0002-8729-2223 Dapeng ZhangSchool of Materials Science and Engineering, East China University of Science and Technology, Shanghai, China.ORCID 0000-0003-4222-6107 Lisa C LindesmithDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0001-9567-0522 Wook-Jin ParkInstitute for RNA Innovation, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID 0000-0002-4514-3967 Jaclynn A MeshanniInstitute for RNA Innovation, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID 0000-0002-1491-3594 Sydni BerkihiserInstitute for RNA Innovation, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID 0009-0008-2051-8153 Jessica A VassermanInstitute for RNA Innovation, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID 0009-0008-0150-1241 Sepideh ToshtzarInstitute for RNA Innovation, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Nathanael C MooreInstitute for RNA Innovation, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID 0009-0008-2252-3175 Blair WilliamsInstitute for RNA Innovation, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Benjamin NakagawaInstitute for RNA Innovation, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID 0009-0009-7529-0210 Ishana BabooInstitute for RNA Innovation, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Liuyan PanSchool of Materials Science and Engineering, East China University of Science and Technology, Shanghai, China.
Wanting ChengSchool of Materials Science and Engineering, East China University of Science and Technology, Shanghai, China.
Xiomara Mercado-LópezInstitute for RNA Innovation, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID 0009-0002-2916-3463 Wendy Bonilla-AcostaInfectious Disease Division, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID 0009-0008-0967-7735 Paul D Brewer-JensenDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0003-0965-8477 Mark R ZweigartDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0001-5765-3203 Yaoska I ReyesDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0001-9467-2438 Michael L MalloryDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0003-0768-572X Samantha R MayDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Yongfeng ZhouSchool of Chemistry and Chemical Engineering, Frontiers Science Center for Transformative Molecules, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0001-6282-5882 Virgil PercecRoy and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-5926-0489 Ralph S BaricDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0001-6827-8701 Yongsheng LiSchool of Materials Science and Engineering, East China University of Science and Technology, Shanghai, China.
Drew WeissmanInstitute for RNA Innovation, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID 0000-0002-1501-6510 Elena N Atochina-VassermanInstitute for RNA Innovation, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID 0000-0001-7950-7004 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
There have been rapid advances in nucleoside-modified messenger RNA-based vaccines, particularly during the SARS-CoV-2 pandemic, demonstrating a rapid and cost-effective approach for addressing infectious diseases. A major challenge remains in developing a delivery system that protects mRNA from degradation and facilitates its passage through tissue and cellular barriers. Current four-component lipid nanoparticles enable efficient endosomal escape and are a pivotal technology for the delivery of mRNA vaccines. However, challenges such as stability, availability, durability, and adverse effects persist. We have developed a self-assembling one-component ionizable amphiphilic Janus dendrimers (IAJD) delivery system with naturally occurring amino heads, capable of efficiently delivering mRNA to the spleen and lymph nodes. This single-component system simplifies synthesis, reduces development complexity, and enables rapid global distribution of mRNA vaccines during pandemics. As a proof of concept, one-component IAJD97, formulated with mRNA encoding norovirus mRNA capsid protein, demonstrates the potential of IAJDs as efficient delivery platform for mRNA vaccines, advancing their effectiveness and expanding applications to improve public health outcomes.
Indexed as
COVID-19COVID-19 VaccinesDendrimersmRNA VaccinesRNA, MessengerVaccine DevelopmentAnimalsHumansMiceNanoparticlesSARS-CoV-2COVID-19 VaccinesDendrimersmRNA VaccinesRNA, Messenger
Identifiers
PMID41894505
PMCPMC13025126
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390